BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36555598)

  • 1. A Pan-Cancer Landscape of ABCG2 across Human Cancers: Friend or Foe?
    Lyu C; Wang L; Stadlbauer B; Buchner A; Pohla H
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
    Reustle A; Fisel P; Renner O; Büttner F; Winter S; Rausch S; Kruck S; Nies AT; Hennenlotter J; Scharpf M; Fend F; Stenzl A; Bedke J; Schwab M; Schaeffeler E
    Int J Cancer; 2018 Dec; 143(12):3181-3193. PubMed ID: 30070687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stemness and anti-cancer drug resistance in ATP-binding cassette subfamily G member 2 highly expressed pancreatic cancer is induced in 3D culture conditions.
    Sasaki N; Ishiwata T; Hasegawa F; Michishita M; Kawai H; Matsuda Y; Arai T; Ishikawa N; Aida J; Takubo K; Toyoda M
    Cancer Sci; 2018 Apr; 109(4):1135-1146. PubMed ID: 29444383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug efflux transporter ABCG2: expression and regulation.
    Kukal S; Guin D; Rawat C; Bora S; Mishra MK; Sharma P; Paul PR; Kanojia N; Grewal GK; Kukreti S; Saso L; Kukreti R
    Cell Mol Life Sci; 2021 Nov; 78(21-22):6887-6939. PubMed ID: 34586444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. sATP‑binding cassette subfamily G member 2 enhances the multidrug resistance properties of human nasal natural killer/T cell lymphoma side population cells.
    Wu S; Zhang X; Dong M; Yang Z; Zhang M; Chen Q
    Oncol Rep; 2020 Oct; 44(4):1467-1478. PubMed ID: 32945520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
    Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
    Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABCG2 is a potential prognostic marker of overall survival in patients with clear cell renal cell carcinoma.
    Wang H; Luo F; Zhu Z; Xu Z; Huang X; Ma R; He H; Zhu Y; Shao K; Zhao J
    BMC Cancer; 2017 Mar; 17(1):222. PubMed ID: 28347288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2.
    Han B; Zhang JT
    Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):31-42. PubMed ID: 14754410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Combined Bioinformatic and Nanoparticle-Based Study Reveal the Role of ABCG2 in the Drug Resistant Breast Cancer.
    Huo Q; Yuan J; Zhu T; Li Z; Xie N
    Recent Pat Anticancer Drug Discov; 2021; 16(3):393-406. PubMed ID: 33602075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between adenosine triphosphate (ATP)-binding cassette transporter G2 (ABCG2) and drug resistance of esophageal cancer and reversal of drug resistance by artesunate.
    Wang L; Liu L; Chen Y; Du Y; Wang J; Liu J
    Pathol Res Pract; 2018 Sep; 214(9):1467-1473. PubMed ID: 30104076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme.
    Oberstadt MC; Bien-Möller S; Weitmann K; Herzog S; Hentschel K; Rimmbach C; Vogelgesang S; Balz E; Fink M; Michael H; Zeden JP; Bruckmüller H; Werk AN; Cascorbi I; Hoffmann W; Rosskopf D; Schroeder HW; Kroemer HK
    BMC Cancer; 2013 Dec; 13():617. PubMed ID: 24380367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased JNK1 signaling pathway is responsible for ABCG2-mediated multidrug resistance in human colon cancer.
    Zhu MM; Tong JL; Xu Q; Nie F; Xu XT; Xiao SD; Ran ZH
    PLoS One; 2012; 7(8):e41763. PubMed ID: 22870247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequence mutations of the substrate binding pocket of stem cell factor and multidrug resistance protein ABCG2 in renal cell cancer: a possible link to treatment resistance.
    Zoernig I; Ziegelmeier C; Lahrmann B; Grabe N; Jäger D; Halama N
    Oncol Rep; 2013 May; 29(5):1697-700. PubMed ID: 23467750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.
    Hasanabady MH; Kalalinia F
    J Biosci; 2016 Jun; 41(2):313-24. PubMed ID: 27240991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2.
    Liu B; Guo Z; Dong H; Daofeng T; Cai Q; Ji B; Zhang S; Wu L; Wang J; Wang L; Zhu X; Liu Y; Chen Q
    Brain Res; 2015 Jun; 1611():93-100. PubMed ID: 25801120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expression of ABCB1, ABCG2, and KLF4 as putative indicators for paclitaxel resistance in human epithelial type 2 cells.
    Duz MB; Karatas OF
    Mol Biol Rep; 2021 Feb; 48(2):1393-1400. PubMed ID: 33506275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
    Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.